Tattoo After Care

Product NDC: 67234-066
11-digit product format: 672340066
Labeler code: 67234
Product ID: 67234-066_9d172c92-66eb-4878-b8ce-0df110014e85
Type: HUMAN OTC DRUG
Nonproprietary name: Lanolin and Petrolatum
Dosage form: OINTMENT
Route: TOPICAL
Labeler: Natureplex LLC
Application: part347
Marketing category: OTC MONOGRAPH FINAL
Marketing start: 2018-06-15
Marketing end: 0000-00-00
Substance: LANOLIN; PETROLATUM
Active strength: 0 mg/g; mg/g
NDC exclude flag: No
Listing certified through: 2020-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded product	product	67234-066		I	Inactivated by FDA		2026-10-16
excluded package	package	67234-066	67234-066-01	I	Inactivated by FDA		2026-10-16

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 18 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Code	Status	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		I	Inactivated by FDA	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	67234-066-01	I	Inactivated by FDA	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		I	Inactivated by FDA	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	67234-066-01	I	Inactivated by FDA	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	67234-066-01	I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	67234-066-01	I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		I	Inactivated by FDA	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	67234-066-01	I	Inactivated by FDA	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		I	Inactivated by FDA	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	67234-066-01	I	Inactivated by FDA	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		U	Excluded because listing certification expired	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	67234-066-01	U	Excluded because listing certification expired	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		U	Excluded because listing certification expired	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	67234-066-01	U	Excluded because listing certification expired	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		U	Excluded because listing certification expired	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	67234-066-01	U	Excluded because listing certification expired	`0efc9e666f02…`	`f202fb6c5f17…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
67234-066-01	2025-01-30	C162847	48780-1	2cef2736-9931-d83d-e063-dadaa90ab31f	Tattoo After Care A&D Ointment

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
67234-066-01	Tattoo After Care A and D	42.5 g in 1 TUBE	OINTMENT	42.5		1
67234-066-01	Tattoo After Care A and D	1 in 1 CARTON	OINTMENT	1		1

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
67234-066	TATTOO AFTER CARE A AND D (LANOLIN AND PETROLATUM) OINTMENT [NATUREPLEX LLC]	1	Legacy NDC, 2 package rows	20180615_e12667d7-31a4-4a15-a7de-8f46191f80e3.zip

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
7EV65EAW6H	LANOLIN	8006-54-0	LANOLIN
4T6H12BN9U	PETROLATUM	8009-03-8	PETROLATUM

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
664981	lanolin 15.5 % / petrolatum 53.4 % Topical Ointment	PSN	e12667d7-31a4-4a15-a7de-8f46191f80e3	1
664981	lanolin 0.155 MG/MG / petrolatum 0.534 MG/MG Topical Ointment	SCD	e12667d7-31a4-4a15-a7de-8f46191f80e3	1
664981	lanolin 15.5 % / petrolatum 53.4 % Topical Ointment	SY	e12667d7-31a4-4a15-a7de-8f46191f80e3	1
664981	lanolin 15.5 GM per 100 GM / petrolatum 53.4 GM per 100 GM Topical Ointment	SY	e12667d7-31a4-4a15-a7de-8f46191f80e3	1

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Marketing start	Marketing end	Sample	Exclude flag	Status
67234-066-01	67234006601	1 TUBE in 1 CARTON (67234-066-01) > 42.5 g in 1 TUBE	1 tube	2018-06-15	0000-00-00	No	No	Current